



## Peptide-Based Vaccines against Infectious Diseases and Cancer

Guest Editors:

**Dr. Waleed Hussein**

Institute for Molecular  
Bioscience, The University of  
Queensland, Brisbane, Australia

**Dr. Rachel Stephenson**

School of Chemistry and  
Molecular Biosciences, The  
University of Queensland,  
Brisbane, Australia

**Dr. Mariusz Skwarczynski**

School of Chemistry and  
Molecular Biosciences, The  
University of Queensland, St  
Lucia, QLD 4072, Australia

### Message from the Guest Editors

Vaccination is one of the most successful tools for reducing the incidence of infectious diseases. Peptide-based subunit vaccines have emerged as promising prophylactic and therapeutic medication against several infectious diseases including group A streptococcus, malaria, TB, and cancer. Peptide-subunit-based vaccines contain only the minimal immunogenic region of an antigen necessary to elicit the desired immune response. Therefore, only safe and effective epitopes can be selected, removing the risk of allergic and autoimmune responses. However, peptides do not contain the danger signals that are needed to activate the immune system. Thus, an adjuvant/delivery system must be included to stimulate an immune response against the peptide antigen.

Deadline for manuscript  
submissions:

**closed (31 October 2023)**





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)